These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 35605657)
1. Neuroblastoma: Essential genetic pathways and current therapeutic options. Salemi F; Alam W; Hassani MS; Hashemi SZ; Jafari AA; Mirmoeeni SMS; Arbab M; Mortazavizadeh SMR; Khan H Eur J Pharmacol; 2022 Jul; 926():175030. PubMed ID: 35605657 [TBL] [Abstract][Full Text] [Related]
2. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed Liu T; Merguerian MD; Rowe SP; Pratilas CA; Chen AR; Ladle BH Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34210658 [TBL] [Abstract][Full Text] [Related]
4. Quantitative Proteomics of Th-MYCN Transgenic Mice Reveals Aurora Kinase Inhibitor Altered Metabolic Pathways and Enhanced ACADM To Suppress Neuroblastoma Progression. Hsieh CH; Cheung CHY; Liu YL; Hou CL; Hsu CL; Huang CT; Yang TS; Chen SF; Chen CN; Hsu WM; Huang HC; Juan HF J Proteome Res; 2019 Nov; 18(11):3850-3866. PubMed ID: 31560547 [TBL] [Abstract][Full Text] [Related]
5. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas. Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034 [TBL] [Abstract][Full Text] [Related]
6. New Approaches Towards Targeted Therapy for Childhood Neuroblastoma. Dalianis T; Lukoseviciute M; Holzhauser S; Kostopoulou ON Anticancer Res; 2023 Sep; 43(9):3829-3839. PubMed ID: 37648295 [TBL] [Abstract][Full Text] [Related]
7. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590 [TBL] [Abstract][Full Text] [Related]
8. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma. Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342 [TBL] [Abstract][Full Text] [Related]
9. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model. Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243 [TBL] [Abstract][Full Text] [Related]
10. Mutations in PIK3CA are infrequent in neuroblastoma. Dam V; Morgan BT; Mazanek P; Hogarty MD BMC Cancer; 2006 Jul; 6():177. PubMed ID: 16822308 [TBL] [Abstract][Full Text] [Related]
11. Development of treatment strategies for advanced neuroblastoma. Hara J Int J Clin Oncol; 2012 Jun; 17(3):196-203. PubMed ID: 22588779 [TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Yalçin B; Kremer LC; van Dalen EC Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD006301. PubMed ID: 26436598 [TBL] [Abstract][Full Text] [Related]
17. PI3King the lock: targeting the PI3K/Akt/mTOR pathway as a novel therapeutic strategy in neuroblastoma. King D; Yeomanson D; Bryant HE J Pediatr Hematol Oncol; 2015 May; 37(4):245-51. PubMed ID: 25811750 [TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
19. Current management of neuroblastoma and future direction. Pastor ER; Mousa SA Crit Rev Oncol Hematol; 2019 Jun; 138():38-43. PubMed ID: 31092383 [TBL] [Abstract][Full Text] [Related]
20. Targeted Therapy for Neuroblastoma: ALK Inhibitors. Schulte JH; Schulte S; Heukamp LC; Astrahantseff K; Stephan H; Fischer M; Schramm A; Eggert A Klin Padiatr; 2013 Nov; 225(6):303-8. PubMed ID: 24166094 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]